Grover Shrruti K, Agarwal Sarla, Gupta Sanjay, Wadhwa Neelam, Sharma Nivedita
Department of Pathology, University College of Medical Sciences & GTB Hospital, B-37/7, Double Storey, Ramesh Nagar, New Delhi, 110015, India,
Pathol Oncol Res. 2015 Jul;21(3):651-7. doi: 10.1007/s12253-014-9870-y. Epub 2014 Dec 20.
Estrogen regulates the growth of prostate through two receptors Estrogen receptor α & β of which ERβ is proposed to be antiproliferative. There is a wide variation in the results of various studies regarding the localisation, level of expression of ERβ in benign & malignant lesions of prostate and its relation to the grade of tumor emphasizing the need for additional studies to standardize the distribution of this receptor in prostate. This was a prospective study conducted in Department of Pathology, UCMS, Delhi, evaluating ERβ & Ki 67 immunoexpression in 60 cases of benign and malignant lesions of prostate (30 each). Tissue for study included prostatic core biopsy and TURP chips. After histomorphological diagnosis, immunohistochemical staining was performed using a monoclonal antibody. Nuclear expression of ERβ & Ki67 was evaluated and compared between the two study groups (benign & malignant lesions) using Pearson chi square test. ERβ was predominantly localized to nuclei of secretory epithelium of prostatic glands. Expression of ERβ was higher in benign glands compared to carcinoma. However, majority of carcinomas retained ERβ expression though at much lower levels. Expression of Ki 67 was higher in carcinoma than benign hyperplasia. There was no correlation between the ERβ status, Ki 67 expression & grade of tumor. Expression of ERβ is downregulated in carcinoma compared to benign hyperplasia and is consistent with its chemopreventive role in prostate. It might have a therapeutic implication as agonists' targeting this receptor could be a part of treatment protocol for those patients of carcinoma who retain this receptor at significant levels.
雌激素通过雌激素受体α和β这两种受体调节前列腺的生长，其中雌激素受体β被认为具有抗增殖作用。关于雌激素受体β在前列腺良性和恶性病变中的定位、表达水平及其与肿瘤分级的关系，各种研究结果存在很大差异，这凸显了开展更多研究以规范该受体在前列腺中分布情况的必要性。这是一项在德里大学医学院病理科进行的前瞻性研究，评估了60例前列腺良性和恶性病变（各30例）中雌激素受体β和Ki 67的免疫表达情况。研究组织包括前列腺芯针活检标本和经尿道前列腺电切术碎片。在进行组织形态学诊断后，使用单克隆抗体进行免疫组织化学染色。采用Pearson卡方检验评估并比较两个研究组（良性和恶性病变）中雌激素受体β和Ki 67的核表达情况。雌激素受体β主要定位于前列腺腺泡分泌上皮的细胞核。与癌组织相比，良性腺体内雌激素受体β的表达更高。然而，大多数癌组织仍保留雌激素受体β表达，尽管水平低得多。Ki 67在癌组织中的表达高于良性增生组织。雌激素受体β状态、Ki 67表达与肿瘤分级之间无相关性。与良性增生相比，癌组织中雌激素受体β的表达下调，这与其在前列腺中的化学预防作用一致。它可能具有治疗意义，因为针对该受体的激动剂可能成为那些仍大量保留该受体的前列腺癌患者治疗方案的一部分。
